MAY 13, 2015 06:00 AM PDT

Predictive Gene Signatures: Molecular Markers Distinguishing Colon Adenomatous Polyp and Carcinoma

Speakers
  • Senior Research Fellow, MSc Human Nutrition, Course Co-ordinator for Molecular Nutrition, University of Aberdeen, Rowett Institute of Nutrition and Health, Metabolic Health Group
    Biography
      Dr. Janice Drew is a Senior Research Fellow in the Rowett Institute of Nutrition and Health within the College of Life Sciences and Medicine at the University of Aberdeen. She received a BSc Hons (First Class) degree from the University of Strathclyde (Glasgow, UK) in 1991 conducting her honours project on plant bioactives produced from genetically transformed root cultures. She pursued graduate work at the University of Durham (UK) and received her Ph.D. in molecular biology in 1994. Subsequently, Dr. Drew trained as a postdoctoral fellow in molecular neuroendocrinology, investigating G protein coupled receptor signalling in circadian rhythms and appetite and energy balance at the Rowett Research Institute (Aberdeen, UK) supported by a Strategic Alliance with Servier (France).

      Dr. Drew has developed research programmes in cross therapeutic areas investigating diet:gene interactions and links with gut and metabolic health. Her work utilises systems approaches incorporating genomic, proteomic, biochemical and physiological analyses to identify molecular mechanisms linking diet and lifestyle factors to gut and metabolic health. Her research in this area has investigated regulatory pathways of genes involved in key processes such as, proliferation, differentiation and apoptosis, inflammation and signalling systems such as adipokine and endocannabinoid, using in vitro cell and ex vivo human colon explant cultures, in vivo models, tissue and organ systems, blood profiling and human intervention studies. Her current focus is directed to study of the regulation and modulation of the sirtuin/NAD system as a nutrient and stress sensor and associations with metabolic health status, cancer and longevity.

    Abstract:

    Cancers exhibit abnormal molecular signatures associated with disease initiation and progression. Molecular signatures could improve cancer screening, detection, drug development and selection of appropriate therapeutic interventions for individual patients. Typically only very small amounts of tissue are available from patients for analysis and biopsy samples exhibit broad heterogeneity that cannot be captured using a single marker. This presentation details application of in-house custom designed GenomeLab System multiplex gene expression assays. Details of design, tissue optimisation, total RNA quality and analytical and clinical validation will be discussed. Application to assess predictive gene signatures of normal, adenomatous polyp and carcinoma colon tissue using archived tissue bank material and an in-house custom designed human cell marker multiplex, the hCellMarkerPlex will be presented. The hCellMarkerPlex incorporates twenty-one gene markers: epithelial (EZR, KRT18, NOX1, SLC9A2), proliferation (PCNA, CCND1, MS4A12), differentiation (B4GANLT2, CDX1, CDX2), apoptotic (CASP3, NOX1, NTN1), fibroblast (FSP1, COL1A1), structural (ACTG2, CNN1, DES), gene transcription (HDAC1), stem cell (LGR5), endothelial (VWF) and mucin production (MUC2). Gene signatures distinguished normal, adenomatous polyp and carcinoma. Individual gene targets significantly contributing to molecular tissue types, classifier genes, were further characterised using real-time PCR, in-situ hybridisation and immunohistochemistry revealing aberrant epithelial expression of MS4A12, LGR5 CDX2, NOX1 and SLC9A2 prior to development of carcinoma. Identified gene signatures identify aberrant epithelial expression of genes prior to cancer development using in-house custom designed gene expression multiplex assays. This approach may be used to assist in objective classification of disease initiation, staging, progression and therapeutic responses using tissue biopsy material.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    MAR 26, 2019 02:00 PM PDT
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    Loading Comments...
    Show Resources